Medivation

Last updated
Medivation, Inc.
Industry Pharmaceutical industry
Founded2004
Headquarters
San Francisco, California
,
United States
Key people
 David Hung & Steve Gorlin
Owner Pfizer
Website medivation.com

Medivation was an American biopharmaceutical company focused on development of novel therapies to treat serious diseases for which there are limited treatment options. Medivation was headquartered in San Francisco, California, beginning operations in December 2004 with the acquisition of Medivation Neurology, Inc. [1] Its final CEO was David Hung. [2]

Contents

Medivation, in collaboration with Astellas, was in development of enzalutamide for multiple stages of prostate cancer and for breast cancer. On August 31, 2012, Medivation and Astellas announced that the U.S. Food and Drug Administration (FDA) granted approval to XTANDI (enzalutamide) capsules for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel. XTANDI is an oral, once-daily androgen receptor inhibitor. [3]

Pfizer announced it would acquire the company in August 2016 for $14 billion and completed the acquisition in October 2016. [4]

Company history

Steve Gorlin [5] and David Hung founded Medivation in 2003. After watching a 28-year-old breast cancer patient die during his oncology fellowship David Hung said he must do something about it. [6]

2010 – Class action lawsuit

On March 3, 2010, Medivation's stock dropped $27.15 per share to close at $13.10, a 67% one-day decline on volume of 45 million shares. [7] In response, a security fraud class-action lawsuit was initiated by Izard Nobel LLP, [8] alleging that Medivation made false and misleading statements regarding the effectiveness of Dimebon as a treatment for Alzheimer's disease, before being revealed that it did not meet primary and secondary goals in a Phase 3 trial for patients with mild to moderate Alzheimer's disease. [7]

The counsel for the case was Bernstein Liebhard and the lead plaintiffs were initially David Applestein [9] [10] then Catoosa Fund, LP. On March 22, 2012, the case was dismissed with prejudice. [11] The plaintiffs appealed the dismissal in the Ninth Circuit Court of Appeals. The Ninth Circuit granted oral argument which was held on Friday, January 17, 2014. [12] On March 7, 2014, the Ninth Circuit affirmed the dismissal of the class action, Catoosa Fund LP v. Medivation, Inc., No. 12-15960. The Ninth Circuit stated "With the exception of the tenuous and unattributed statement that Dr. Schneider relates secondhand, plaintiff has not pled any facts supporting an inference of actual knowledge by defendants. Plaintiff relies heavily on the inference that, due to their positions, the defendants must have known about the unmatched nature of the study. That inference is entirely speculative and does not rise to the required strong inference; plaintiff's allegation is not at least as compelling as any opposing inference one could draw from the facts alleged." [13]

2016

In April, the company was linked with a number of potential acquirers including Roche, AstraZeneca, Amgen and Gilead Sciences, and a possible hostile bid from Sanofi. [14] AstraZeneca was reported to weigh in with an offer of £7 billion ($10 billion). [15] On April 29, Sanofi launched a $9.3 billion takeover offer which was rejected by the Medivation board. [16]

Other suitors were Celgene and Genentech, which ultimately lost to Pfizer. [17]

In August, Pfizer announced that it would acquire the company for $14 billion [18] or $81.50 per share, a 21% premium over the closing price on August 19; [19] the acquisition was completed September 28, 2016.

Awards

Medivation CEO David Hung was the EY Entrepreneur of the Year 2014 National Winner. [20]

Related Research Articles

<span class="mw-page-title-main">Pfizer</span> American multinational pharmaceutical and biotechnology corporation

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer (1824–1906) and his cousin Charles F. Erhart (1821–1891).

<span class="mw-page-title-main">AstraZeneca</span> British pharmaceutical company

AstraZeneca plc (AZ) is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It has been involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index. In 2023, the company’s seat in Forbes Global 2000 was 89.

Kaye Scholer was a law firm founded in 1917 by Benjamin Kaye and Jacob Scholer. The firm had more than 450 attorneys in nine offices located in the cities of Chicago, Frankfurt, London, Los Angeles, New York City (headquarters), Shanghai, Palo Alto, Washington, D.C., and West Palm Beach.

<span class="mw-page-title-main">Evercore</span> American financial services company

Evercore Inc., formerly known as Evercore Partners, is a global independent investment banking advisory firm founded in 1995 by Roger Altman, David Offensend, and Austin Beutner. The firm has advised on over $4.7 trillion of merger, acquisition, and restructuring transactions since its founding. Evercore is widely considered one of the most prestigious and elite investment banking advisory firms.

<span class="mw-page-title-main">Vandetanib</span> Chemical compound

Vandetanib, sold under the brand name Caprelsa, is an anti-cancer medication that is used for the treatment of certain tumours of the thyroid gland. It acts as a kinase inhibitor of a number of cell receptors, mainly the vascular endothelial growth factor receptor (VEGFR), the epidermal growth factor receptor (EGFR), and the RET-tyrosine kinase. The drug was developed by AstraZeneca who later sold the rights to Sanofi in 2015.

<span class="mw-page-title-main">Tremelimumab</span> Monoclonal antibody

Tremelimumab, sold under the brand name Imjudo, is a fully human monoclonal antibody used for the treatment of hepatocellular carcinoma. Tremelimumab is designed to attach to and block CTLA-4, a protein that controls the activity of T cells, which are part of the immune system.

<span class="mw-page-title-main">Latrepirdine</span> Antihistamine drug

Latrepirdine is an antihistamine drug which has been used clinically in Russia since 1983.

Sir Menelaos (Mene) Nicolas Pangalos is a British neuroscientist of Greek descent.

Direct factor Xa inhibitors (xabans) are anticoagulants, used to both treat and prevent blood clots in veins, and prevent stroke and embolism in people with atrial fibrillation (AF).

The National Health Council (NHC) is a nonprofit association of health organizations.

The pharmaceutical industry in the United Kingdom directly employs around 73,000 people and in 2007 contributed £8.4 billion to the UK's GDP and invested a total of £3.9 billion in research and development. In 2007 exports of pharmaceutical products from the UK totalled £14.6 billion, creating a trade surplus in pharmaceutical products of £4.3 billion.

<span class="mw-page-title-main">Stefan P. Kruszewski</span> American clinical and forensic psychiatrist

Stefan Philip Kruszewski is an American clinical and forensic psychiatrist, active as a whistleblower in medically related cases. He is principal in the company which bears his name, Stefan P. Kruszewski, M.D. & Associates, P.C. in Harrisburg, Pennsylvania.

<span class="mw-page-title-main">LifeArc</span>

LifeArc is a British life science medical research charity. It was established in 2000 as MRC Technology to translate the work of UK Medical Research Council (MRC) research scientists.

AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74. The company's primary product is Humira (adalimumab), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.

Robbins Geller Rudman & Dowd LLP is an American law firm headquartered in San Diego, California. It is a plaintiffs law firm specializing in securities litigation and shareholder rights cases.

<span class="mw-page-title-main">Juno Therapeutics</span> American biopharmaceutical company

Juno Therapeutics Inc was an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. The company raised $300 million through private funding and a further $265 million through their IPO.

<span class="mw-page-title-main">BioNTech</span> German biotechnology company

BioNTech SE is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. It develops pharmaceutical candidates based on messenger ribonucleic acid (mRNA) for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer.

References

  1. ↑ "Investor relations". Medivation. Archived from the original on 3 July 2007. Retrieved 17 November 2012.
  2. ↑ "Management team". Medivation. Retrieved 17 November 2012.
  3. ↑ "Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Medivation, Inc". Law Offices of Howard G. Smith. 2010-03-03. Archived from the original on 10 August 2014. Retrieved 17 November 2012.
  4. ↑ "Pfizer Completes Acquisition of Medivation". Yahoo! Finance. Retrieved 4 January 2017.
  5. ↑ "Nothing ventured, something gained?". www.bizjournals.com. Retrieved 23 October 2020.
  6. ↑ Rockoff, Jonathan D. (2016-08-23). "Pfizer to Buy Medivation for $14 Billion". Wall Street Journal. ISSN   0099-9660 . Retrieved 2017-12-20.
  7. 1 2 "The Brualdi Law Firm, P.C. Announces Class Action Lawsuit Against Medivation, Inc". New York: Bloomberg L.P. March 12, 2010. Archived from the original on 6 June 2022. Retrieved 17 November 2012.
  8. ↑ Robbins Geller Rudman & Dowd (March 9, 2010). "Class action complaint for violation of the federal securities laws" (PDF). Northern District of California: Izard Nobel LLP. Archived from the original (PDF) on 3 March 2016. Retrieved 17 November 2012.
  9. ↑ "Michael S. Bigin". Bernstein Liebhard LLP. Archived from the original on 24 April 2012. Retrieved 17 November 2012. [Michael S. Bigin] represents investors in Applestein v. Medivation, Inc., No. 10-CV-00998 (EMC) (N.D. Cal.), in which plaintiffs allege that defendants inflated the price of Medivation stock by making false statements concerning the efficacy of its chief drug's treatment of Alzheimer's disease.
  10. ↑ "U. SETH OTTENSOSER". Bernstein Liebhard LLP. Archived from the original on 28 January 2013. Retrieved 17 November 2012. [U. Seth Ottensoser] represents investors in Applestein v. Medivation, Inc., No. 10-CV-00998 (EMC) (N.D. Cal.), in which plaintiffs allege that defendants inflated the price of Medivation stock by making false statements concerning the efficacy of its chief drug's treatment of Alzheimer's disease.
  11. ↑ "Medivation, Inc". Securities class action clearinghouse. Stanford Law School. March 22, 2012. Archived from the original on 16 December 2013. Retrieved 17 November 2012.
  12. ↑ Ninth Circuit. Court of Appeals
  13. ↑ "Unpublished Dispositions (Memoranda)".
  14. ↑ "Sanofi could go hostile with Medivation bid". 13 April 2016.
  15. ↑ "AstraZeneca eyes Xtandi windfall with potential £7B bid for Medivation".
  16. ↑ Joshua Jamerson and Noemie Bisserbe (29 April 2016). "Medivation Rejects Sanofi's $9.3 Billion Takeover Bid". WSJ.
  17. ↑ "Medivation call for offers". Reuters. 29 July 2016.
  18. ↑ "Pfizer to Acquire Medivation for $14B - GEN News Highlights - GEN". 22 August 2016.
  19. ↑ "Pfizer to buy cancer drug firm Medivation for $14bn". BBC News. 22 August 2016.
  20. ↑ Medivation. "Medivation CEO David Hung Named National EY Entrepreneur Of The Year 2014 Overall Award Winner Medivation.com. Medivation, 17 December 2014.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.